Plain Language Study Results Summaries
What Are Plain Language Study Results Summaries?
Plain Language Study Results Summaries are descriptions in everyday language of the design and results of clinical studies. These summaries (also called layperson summaries, plain language summaries, lay language summaries, simple summaries, and trial results summaries) are intended to make the clinical results of these studies understandable and accessible to patients, healthcare providers, caregivers, researchers, and a general audience.
Please use the search function below to find Plain Language Study Results Summaries for Pfizer-sponsored global clinical trials. For more information about a specific study, please visit ClinicalTrials.gov on the ClinicalTrials.gov Identifier (NCT) link on the study results page.
Category & Conditions: Skin Diseases and Conditions
Study Phase : 2
Medicine: EUCRISA™(CRISABOROLE)
PrintDownloadCategory & Conditions: Cancer
Study Phase : 1/2
Medicine: MEKTOVI® TABLETS(BINIMETINIB), OPDIVO®(NIVOLUMAB), YERVOY®(IPILIMUMAB)
PrintDownloadCategory & Conditions: Cancer
Study Phase : 2
Medicine: TALZENNA™(TALAZOPARIB) CAPSULES
PrintDownloadCategory & Conditions: Immune System Diseases and Conditions
Study Phase : 4
Medicine: XELJANZ®(TOFACITINIB)
PrintDownloadCategory & Conditions: Skin Diseases and Conditions
Study Phase : 3
Medicine: abrocitinib (PF-04965842)
PrintDownloadCategory & Conditions: Cancer
Study Phase : 1/2
Medicine: Bavencio (avelumab)
PrintDownloadCategory & Conditions: Cancer
Study Phase : 1/2
Medicine: Bavencio (avelumab), Talzenna (talazoparib)
PrintDownloadCategory & Conditions: Immune System Diseases and Conditions
Study Phase : 2
Medicine: Dekavil
PrintDownloadCategory & Conditions: Rare Diseases
Study Phase : 2
Medicine: marstacimab (PF-06741086)
PrintDownloadCategory & Conditions: Infections and Infectious Diseases
Study Phase : 3
Medicine: PF-06425090
PrintDownloadCategory & Conditions: Vaccine-related Conditions
Study Phase : 2
Medicine: PF-06482077
PrintDownloadCategory & Conditions: Cancer
Study Phase : 1
Medicine: PF-06804103
PrintDownload